What the changes say
- Cybersecurity risk now emphasizes breaches causing data theft, regulatory claims, customer losses and remediation costs.
- Tariff exposure is more specific: Costa Rica faces a 15% rate, while Mexico depends on continuing USMCA exemptions.
- Manufacturing compliance now highlights FDA QMSR inspections, while Smiths Medical integration remains complex and costly.
- Distributor concentration rose to 18% of 2025 revenue from 16% in 2023, though it remained 18% year over year.
What changed since the prior 10-K
New
- NewMarket and Other External Risks
procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential Information
Cyberattacks, employee actions, system failures or unauthorized access could expose personal information and trigger legal, regulatory and remediation costs.
- NewBusiness and Operating Risks
Additionally, the imposition of higher tariffs could undermine the competitiveness of a U.S. based company in the global market and could result in termination of orders by customers, lower demand for products and the loss of market share
Higher U.S. tariffs on Costa Rican imports, or loss of Mexico’s USMCA exemption, could reduce demand, orders and market share.
- NewLegal, Compliance, and Regulatory Risks
If we or our component manufacturers fail to comply with the FDA's Quality Management System Regulation or Good Manufacturing Practice regulations or other requirements, our manufacturing operations could be interrupted, and our product sales and operating results could suffer
Failure by ICU Medical or component manufacturers to meet FDA QMSR or other manufacturing requirements could interrupt production and sales.
- NewRisks Related to our Strategic Transactions
If we fail to effectively complete the integration of our acquired businesses in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed
Poor integration of Smiths Medical could disrupt systems, plants and supply chains, preventing expected synergies and harming operations.
- NewRisks Related to our Strategic Transactions
contract may place substantial burdens on our management resources and financial controls. Decentralization of assembly and manufacturing could place further burdens on management to manage those operations and maintain efficiencies and quality control
Growth, acquisitions, decentralized manufacturing and Smiths Medical acquisition debt could strain management, financial controls, efficiency and future borrowing capacity.
Dropped
- DroppedLegal, Compliance, and Regulatory Risks
The aforementioned EU rules are generally applicable in the EEA. Non-compliance with the above requirements including as determined by a notified body would also prevent us from selling our products in these geographies
- DroppedLegal, Compliance, and Regulatory Risks
manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results
- DroppedLegal, Compliance, and Regulatory Risks
which have issued or may issue in the future will be broad enough to prevent competitors from introducing similar devices, that such patents, if challenged, will be upheld by the courts or that we will be able to prove infringement and damages in litigation
- DroppedRisks Related to our Strategic Transactions
relationships, our corporate culture could be undermined, the quality of our products and customer service could suffer, and our reputation could be harmed, each of which could adversely impact our business, financial condition and results of operations
- DroppedRisks Related to our Strategic Transactions
acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness
Reworded
- 51% rewrittenRisks Related to our Strategic Transactions
If we are unable to effectively manage our internal growth or growth through acquisitions of companies, assets or products, our financial performance may be adversely affected
The Smiths Medical discussion now describes increased business size rather than significant growth, while retaining risks around acquisition integration and management.
- 50% rewrittenMarket and Other External Risks
The evolving and varied views on sustainability and environmental, social and governance ("ESG") initiatives could increase our costs, harm our reputation and adversely impact our financial results
The risk now emphasizes conflicting stakeholder pressures and certain stakeholder expectations, rather than broad pressure to improve the ESG profile.
Was: The increasing focus on sustainability and environmental, social and governance ("ESG") initiatives could increase our costs, harm our reputation and adversely impact our financial results
- 48% rewrittenLegal, Compliance, and Regulatory Risks
Healthcare regulation and reform measures could adversely affect our revenue and financial condition
The risk remains focused on healthcare regulation, reimbursement and cost-containment measures; the ACA example is unchanged.
- 42% rewrittenLegal, Compliance, and Regulatory Risks
The FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development or otherwise increase the costs associated with compliance
The specific 2019 FDA safety-and-performance pathway example was removed and replaced with broader risks from changing U.S. and foreign rules and review times.
Was: In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development or otherwise increase the costs associated with compliance
- 39% rewrittenMarket and Other External Risks
Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer
No substantive change is shown in the supplied text; the cybersecurity heading and supporting discussion are unchanged.
- 30% rewrittenLegal, Compliance, and Regulatory Risks
Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica, can escalate trade wars and could have a meaningful adverse effect on our results of operations
The tariff discussion adds April 2025 Liberation Day measures, including a 10% baseline rate and higher country-specific rates, with further July 2025 developments.
Was: Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico, can escalate trade wars and could have a meaningful adverse effect on our results of operations
- 29% rewrittenBusiness and Operating Risks
Significant sales through distributors expose us to risks that could have a material effect on our results of operations
The revenue concentration figures now cover 2025 and 2024; one distributor represented 18% in both years, replacing 18% in 2024 and 16% in 2023.
- 26% rewrittenLegal, Compliance, and Regulatory Risks
Our ability to market, distribute and sell our products in the U.S. and other countries may be adversely affected if our products fail to comply with the existing laws and regulations, and applicable requirements of the FDA, governmental agencies in other countries, and notified bodies
No substantive change is shown in the supplied text; the medical-device regulatory coverage and examples are unchanged.
All 39 risk factors
Headings as the filing states them, in filing order.
Market and Other External Risks
- 01If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected
- 02If demand for our products were to decline significantly, we might not be able to recover the cost of our expensive automated molding and assembly equipment and tooling, which could have an adverse effect on our financial condition and results of operations
- 03Product development requires substantial investment that may be difficult for us to fund and may be challenging to recover through commercial product sales
- 04If we do not successfully develop and commercialize enhanced or new products that remain competitive with new products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired
- 05Cost volatility or loss of supply of our raw materials could have an adverse effect on our profitability
- 06If we cannot obtain additional custom tooling and equipment on a timely basis to enable us to meet demand for our products, we might be unable to increase our sales or might lose customers, in which case our sales could decline
- 07Heightened inflation, higher interest rates and foreign currency rate fluctuations as a result of global macroeconomic and geopolitical conditions have had and could in the future have a material adverse effect on our operations
- 08Our operating results may be adversely affected by unfavorable economic conditions that affect our customers’ ability to buy our products and our suppliers' demand for payment terms
- 09Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices and volume. If we cannot reduce manufacturing costs of existing and new products to counteract such pricing pressures, our sales may not grow and our profitability may decline
- 10Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer39% rewritten
- 11procedures, will be fully implemented, complied with or effective in protecting our systems, networks and Confidential InformationNew
- 12Our business could suffer if we lose the services of key personnel
- 13The price of our common stock has been and may continue to be highly volatile due to many factors
- 14Climate-related events and other events could harm our business
- 15The evolving and varied views on sustainability and environmental, social and governance ("ESG") initiatives could increase our costs, harm our reputation and adversely impact our financial results50% rewritten
Business and Operating Risks
- 16Additionally, the imposition of higher tariffs could undermine the competitiveness of a U.S. based company in the global market and could result in termination of orders by customers, lower demand for products and the loss of market shareNew
- 17Damage to, or interruptions at, any of our manufacturing facilities or our suppliers' facilities could impair our ability to produce our products
- 18We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition
- 19We may not be successful in achieving expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts and may experience a decline in our profitability, business disruptions or other adverse consequences to our business as a result
- 20The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies
- 21Significant sales through distributors expose us to risks that could have a material effect on our results of operations29% rewritten
Legal, Compliance, and Regulatory Risks
- 22Our ability to market, distribute and sell our products in the U.S. and other countries may be adversely affected if our products fail to comply with the existing laws and regulations, and applicable requirements of the FDA, governmental agencies in other countries, and notified bodies26% rewritten
- 23The FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development or otherwise increase the costs associated with compliance42% rewritten
- 24If we or our component manufacturers fail to comply with the FDA's Quality Management System Regulation or Good Manufacturing Practice regulations or other requirements, our manufacturing operations could be interrupted, and our product sales and operating results could sufferNew
- 25Any of these sanctions could adversely affect our business, financial condition and operating results
- 26Actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards may adversely affect our business, operations and financial performance
- 27We are subject to certain fraud and abuse and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business
- 28Healthcare regulation and reform measures could adversely affect our revenue and financial condition48% rewritten
- 29If others choose to manufacture and sell products similar to or substantially the same as our products, it could have a material adverse effect on our business through loss of unit volume or price erosion, or both, and could adversely affect our ability to secure new business
- 30Litigation, product liability claims or product recalls could be costly and could expose us to loss
- 31Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica, can escalate trade wars and could have a meaningful adverse effect on our results of operations30% rewritten
- 32Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates
- 33International sales pose additional risks related to competition with larger international companies and established local companies and higher credit risk
- 34We are dependent on manufacturing in Mexico and could be adversely affected by that region's increased labor costs and any economic, social or political disruptions
- 35We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws
- 36We are subject to risks associated with doing business outside of the U.S
Risks Related to our Strategic Transactions
- 37If we fail to effectively complete the integration of our acquired businesses in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmedNew
- 38If we are unable to effectively manage our internal growth or growth through acquisitions of companies, assets or products, our financial performance may be adversely affected51% rewritten
- 39contract may place substantial burdens on our management resources and financial controls. Decentralization of assembly and manufacturing could place further burdens on management to manage those operations and maintain efficiencies and quality controlNew
Other Icu Medical 10-Ks
- FY2024 10-K risk factors39 risks
This company's risk profile is dominated by intense competition in infusion and consumable medical devices, heavy manufacturing reliance on single-source suppliers and facilities in Mexico, complex international regulations, and integration challenges following the Smiths Medical acquisition.
Filed Feb 27, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.